Role of interleukin 28b-related gene polymorphisms in chronic hepatitis c and the response to antiviral therapy in koreans

Journal of Clinical Gastroenterology

Volumn 47, Issue 7, 2013, Pages 644-650

  Jung, Young Kul ^a   Kim, Ji Hoon ^b   Ahn, Sung Min ^a   Yang, Jae Won ^c   Park, Sang Jin ^c   Kim, Jong Woo ^c   Yeon, Jong Eun ^b   Kwon, Oh Sang ^a   Kim, Yun Soo ^a   Choi, Duck Joo ^a   Kim, Ju Hyun ^a   Byun, Kwan Soo ^b  

^a Gachon University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c B and C Biopharm Co Ltd   (South Korea)

Author keywords

antiviral therapy; gene polymorphism; hepatitis C virus; IL28B; Korean

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PYROSEQUENCING; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH KOREA; THROMBOCYTE COUNT; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DNA PRIMERS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; VIRAL LOAD;

EID: 84880750646     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182896abf     Document Type: Review

References (26)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.
2. Shin HR, Kim JY, Kim JI, et al. Hepatitis B and C virus prevalence in a rural area of South Korea: the role of acupuncture. Br J Cancer. 2002;87:314-318.
3. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver international. 2009;29(suppl 1):100-107.
4. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49:S45-S55.
5. Kim YS, Um SH, Ryu HS, et al. The prognosis of liver cirrhosis in recent years in Korea. J Korean Med Sci. 2003;18:833-841.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
7. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa- 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
8. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
9. Myers RP, Patel K, Pianko S, et al. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. J Viral Hepat. 2003;10:16-22.
10. Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007;45:80-87.
11. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470-477.
12. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
13. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-1109.
14. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nat Genet. 2009;41:1100-1104.
15. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798-801.
16. Gaunt TR, Rodriguez S, Day IN. Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'. BMC Bioinformatics. 2007;8:428.
17. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010;138:2307-2314.
18. Sarrazin C, Susser S, Doehring A, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol. 2011;54:415-421.
19. Maher SG, Sheikh F, Scarzello AJ, et al. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther. 2008;7:1109-1115.
20. Dumoutier L, Tounsi A, Michiels T, et al. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem. 2004;279:32269-32274.
21. Missiha S, Heathcote J, Arenovich T, et al. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol. 2007;102:2181-2188.
22. Sinn DH, Kim YJ, Lee ST, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J Gastroenterol Hepatol. 2011;26:1374-1379.
23. Kim JI, Kim SH, Lee BS, et al. Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: a comparative study. Korean J Hepatol. 2008;14: 493-502.
24. Lee H, Choi MS, Paik SW, et al. Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea. Korean J Hepatol. 2006;12:31-40.
25. Faruki H, Albrecht J, Morrison P, et al. Genotype frequencies of IL28B genetic polymorphisms rs12979860 and rs8099917 in a large genetic database of various ethnic/racial origin individials. Hepatology. 2011;54(suppl):816A.
26. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54: 1433-1444.